BRPI0921927A2 - sensibilização de uma resposta imune - Google Patents
sensibilização de uma resposta imuneInfo
- Publication number
- BRPI0921927A2 BRPI0921927A2 BRPI0921927A BRPI0921927A BRPI0921927A2 BR PI0921927 A2 BRPI0921927 A2 BR PI0921927A2 BR PI0921927 A BRPI0921927 A BR PI0921927A BR PI0921927 A BRPI0921927 A BR PI0921927A BR PI0921927 A2 BRPI0921927 A2 BR PI0921927A2
- Authority
- BR
- Brazil
- Prior art keywords
- sensitization
- immune response
- immune
- response
- Prior art date
Links
- 206010070834 Sensitisation Diseases 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000008313 sensitization Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200801638 | 2008-11-21 | ||
DKPA200801638 | 2008-11-21 | ||
PCT/DK2009/050310 WO2010057501A1 (en) | 2008-11-21 | 2009-11-20 | Priming of an immune response |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0921927A2 true BRPI0921927A2 (pt) | 2016-04-26 |
BRPI0921927B1 BRPI0921927B1 (pt) | 2021-06-15 |
BRPI0921927B8 BRPI0921927B8 (pt) | 2021-08-31 |
Family
ID=40823418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921927A BRPI0921927B8 (pt) | 2008-11-21 | 2009-11-20 | Sensibilização de uma resposta imune |
Country Status (20)
Country | Link |
---|---|
US (4) | US20110293704A1 (pt) |
EP (3) | EP2865387B1 (pt) |
JP (4) | JP2012509071A (pt) |
CN (3) | CN102292102A (pt) |
AU (1) | AU2009317691A1 (pt) |
BR (1) | BRPI0921927B8 (pt) |
CA (1) | CA2743229A1 (pt) |
CY (1) | CY1122117T1 (pt) |
DK (1) | DK2865387T3 (pt) |
ES (1) | ES2743677T3 (pt) |
HK (1) | HK1209645A1 (pt) |
HR (1) | HRP20191594T1 (pt) |
HU (1) | HUE045093T2 (pt) |
IL (4) | IL212914A0 (pt) |
LT (1) | LT2865387T (pt) |
PL (1) | PL2865387T3 (pt) |
PT (1) | PT2865387T (pt) |
RU (2) | RU2011125306A (pt) |
SI (1) | SI2865387T1 (pt) |
WO (1) | WO2010057501A1 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3000487B8 (en) | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
BR112012030794B1 (pt) * | 2010-06-04 | 2019-11-26 | Inserm ( Institut National De La Santé Et De La Recherche Médicale) | Novos compostos imunoadjuvantes e usos dos mesmos |
GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
EP4092415A1 (en) | 2011-12-07 | 2022-11-23 | Belgian Volition Srl | Method for detecting nucleosome adducts |
US9962436B2 (en) | 2012-07-26 | 2018-05-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
ES2741207T3 (es) | 2013-03-15 | 2020-02-10 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos, y métodos de uso de los mismos |
KR102354389B1 (ko) * | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
PL3086815T3 (pl) | 2013-12-27 | 2022-06-13 | Zymeworks Inc. | Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe |
US10675355B2 (en) * | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
IL287645B2 (en) | 2014-09-17 | 2024-04-01 | Zymeworks Bc Inc | Cytotoxic and anti-mitotic compounds and methods for their use |
WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
CA3003302A1 (en) | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
CA3034124A1 (en) * | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
CN111093699A (zh) * | 2017-07-12 | 2020-05-01 | Nouscom股份公司 | 用于治疗癌症的新抗原疫苗组合物 |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
EP3703744A1 (en) * | 2017-11-03 | 2020-09-09 | Nouscom AG | Vaccine t cell enhancer |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
CN108285885A (zh) * | 2017-12-28 | 2018-07-17 | 中国农业大学 | 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用 |
EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
US20210379169A1 (en) * | 2018-10-19 | 2021-12-09 | Nouscom Ag | Teleost invariant chain cancer vaccine |
EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
RU2725493C2 (ru) * | 2018-12-28 | 2020-07-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора |
TW202102256A (zh) | 2019-03-05 | 2021-01-16 | 比利時商葛蘭素史密斯克藍生物品公司 | B型肝炎免疫法及組合物 |
CN111729093B (zh) * | 2020-06-29 | 2022-05-24 | 南京超维景生物科技有限公司 | 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法 |
EP4137153A1 (en) | 2021-08-18 | 2023-02-22 | Sirion Biotech GmbH | Therapeutic papilloma virus vaccines |
WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US58767A (en) | 1866-10-16 | John brougjbton | ||
US587673A (en) | 1897-08-03 | higgins | ||
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
JP2682061B2 (ja) | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
US5559028A (en) * | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
US5876735A (en) | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
AU3307497A (en) * | 1996-06-26 | 1998-01-14 | Antigen Express, Inc. | Immunotherapy by modulation of antigen presentation |
CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
EP1957528B1 (en) * | 2005-11-30 | 2012-11-07 | University of Copenhagen | A nucleotide vaccine |
US20080095798A1 (en) * | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
US9085638B2 (en) * | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
WO2010027973A1 (en) * | 2008-09-02 | 2010-03-11 | Antigen Express, Inc. | Human papillomavirus / li-key hybrids and methods of use |
-
2009
- 2009-11-20 DK DK15152408.9T patent/DK2865387T3/da active
- 2009-11-20 CN CN2009801549244A patent/CN102292102A/zh active Pending
- 2009-11-20 US US13/129,857 patent/US20110293704A1/en not_active Abandoned
- 2009-11-20 ES ES15152408T patent/ES2743677T3/es active Active
- 2009-11-20 CN CN201710007117.6A patent/CN107090472A/zh active Pending
- 2009-11-20 RU RU2011125306/10A patent/RU2011125306A/ru unknown
- 2009-11-20 PT PT15152408T patent/PT2865387T/pt unknown
- 2009-11-20 AU AU2009317691A patent/AU2009317691A1/en not_active Abandoned
- 2009-11-20 LT LTEP15152408.9T patent/LT2865387T/lt unknown
- 2009-11-20 PL PL15152408T patent/PL2865387T3/pl unknown
- 2009-11-20 CA CA2743229A patent/CA2743229A1/en active Pending
- 2009-11-20 JP JP2011536741A patent/JP2012509071A/ja active Pending
- 2009-11-20 SI SI200931996T patent/SI2865387T1/sl unknown
- 2009-11-20 BR BRPI0921927A patent/BRPI0921927B8/pt active Search and Examination
- 2009-11-20 HU HUE15152408A patent/HUE045093T2/hu unknown
- 2009-11-20 EP EP15152408.9A patent/EP2865387B1/en active Active
- 2009-11-20 EP EP09760468A patent/EP2355842A1/en not_active Withdrawn
- 2009-11-20 RU RU2017138373A patent/RU2017138373A/ru not_active Application Discontinuation
- 2009-11-20 CN CN201410485599.2A patent/CN104404068A/zh active Pending
- 2009-11-20 EP EP19173464.9A patent/EP3552622A3/en active Pending
- 2009-11-20 WO PCT/DK2009/050310 patent/WO2010057501A1/en active Application Filing
-
2011
- 2011-05-16 IL IL212914A patent/IL212914A0/en unknown
-
2014
- 2014-06-16 IL IL233175A patent/IL233175A0/en unknown
- 2014-06-16 IL IL233174A patent/IL233174A0/en unknown
- 2014-06-16 IL IL233176A patent/IL233176A0/en unknown
- 2014-09-10 US US14/482,452 patent/US20150056227A1/en not_active Abandoned
- 2014-11-07 JP JP2014226711A patent/JP2015061530A/ja active Pending
-
2015
- 2015-10-28 HK HK15110589.9A patent/HK1209645A1/xx unknown
-
2017
- 2017-01-26 JP JP2017011749A patent/JP2017131220A/ja active Pending
- 2017-04-25 US US15/496,045 patent/US20170290898A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019091809A patent/JP6825036B2/ja active Active
- 2019-09-02 CY CY20191100920T patent/CY1122117T1/el unknown
- 2019-09-04 HR HRP20191594 patent/HRP20191594T1/hr unknown
-
2021
- 2021-06-17 US US17/350,971 patent/US20210386842A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921927A2 (pt) | sensibilização de uma resposta imune | |
BRPI0910464A2 (pt) | estimulação de uma resposta imune por enantiômeros de lipídios catiônicos | |
BRPI0906888A2 (pt) | derivado de fenilacetamida | |
SMT201500268B (it) | Derivato di 5-idrossipirimidin-4-carbossammide | |
DE112010000691A5 (de) | Chromatographievorrichtung | |
IT1398296B1 (it) | Disposizione di sensori | |
FI20096192A (fi) | Kohteen valaiseminen | |
ES1069629Y (es) | Mueble | |
CN301210581S (zh) | 电饭锅 | |
TH96239B (th) | หม้อหุงข้าว | |
EE00830U1 (et) | Meetod toidu valmistamiseks | |
IT1400028B1 (it) | Piano di cottura | |
UA16959S (uk) | Набір електротехнічних виробів | |
ES1071211Y (es) | Mueble expositor de piezas ceramicas | |
UA17116S (uk) | Набір офісних меблів | |
TH108432B (th) | สายหัดเดิน | |
EE00890U1 (et) | Kokkukiv trepp | |
TH106204B (th) | ตู้เสื้อผ้า | |
UA19324S (uk) | Шафа | |
TH106203B (th) | ตู้เสื้อผ้า | |
UA19881S (uk) | Шафа | |
UA19882S (uk) | Шафа | |
UA18827S (uk) | Шафа | |
UA19883S (uk) | Шафа | |
UA20036S (uk) | Шафа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2622 DE 06/04/2021. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2632, QUANTO AO QUADRO REIVINDICATORIO |